Cargando…

The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer

Rexinoids are ligands which activate retinoid X receptors (RXRs), regulating transcription of genes involved in cancer-relevant processes. Rexinoids have anti-neoplastic activity in multiple preclinical studies. Bexarotene, used to treat cutaneous T cell lymphoma, is the only FDA-approved rexinoid....

Descripción completa

Detalles Bibliográficos
Autores principales:	Reich, Lyndsey A., Moerland, Jessica A., Leal, Ana S., Zhang, Di, Carapellucci, Sarah, Lockwood, Beth, Jurutka, Peter W., Marshall, Pamela A., Wagner, Carl E., Liby, Karen T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742020/ https://www.ncbi.nlm.nih.gov/pubmed/34997154 http://dx.doi.org/10.1038/s41598-021-04415-0

Ejemplares similares

The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer
por: Moerland, Jessica A., et al.
Publicado: (2020)

Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models
por: Leal, Ana S., et al.
Publicado: (2019)

The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer
por: Leal, Ana S., et al.
Publicado: (2021)

Dataset on the response of Hut78 cells to novel rexinoids
por: Hackney Price, Jennifer, et al.
Publicado: (2018)

Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles
por: Marshall, Pamela A, et al.
Publicado: (2015)

Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice
por: Zhang, Di, et al.
Publicado: (2021)

Rexinoids Modulate Effector T Cell Expression of Mucosal Homing Markers CCR9 and α4β7 Integrin and Direct Their Migration In Vitro
por: Manhas, Kavita R., et al.
Publicado: (2022)

The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner
por: Moerland, Jessica A., et al.
Publicado: (2023)

The Novel RXR Agonist MSU-42011 Differentially Regulates Gene Expression in Mammary Tumors of MMTV-Neu Mice
por: Reich, Lyndsey A., et al.
Publicado: (2023)

A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
por: Zhang, Di, et al.
Publicado: (2019)

Oral retinoids and rexinoids in cutaneous T-cell lymphomas
por: Sokołowska-Wojdyło, Małgorzata, et al.
Publicado: (2013)

Prevention and Treatment of Experimental Estrogen Receptor – Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268
por: Liby, Karen, et al.
Publicado: (2008)

The Multi-Faceted Consequences of NRF2 Activation throughout Carcinogenesis
por: Occhiuto, Christopher J., et al.
Publicado: (2023)

The “Phantom Effect” of the Rexinoid LG100754: Structural and Functional Insights
por: Sato, Yoshiteru, et al.
Publicado: (2010)

Multi-Omics Approach to Dissect the Mechanisms of Rexinoid Signaling in Myoblast Differentiation
por: Khilji, Saadia, et al.
Publicado: (2021)

Complex effects of rexinoids on ligand dependent activation or inhibition of the xenobiotic receptor, CAR
por: Tzameli, Iphigenia, et al.
Publicado: (2003)

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice
por: Li, Y, et al.
Publicado: (2008)

Methyl Substitution of a Rexinoid Agonist Improves Potency and Reveals Site of Lipid Toxicity
por: Atigadda, Venkatram R., et al.
Publicado: (2014)

The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer
por: Leal, Ana S., et al.
Publicado: (2020)

Insights into interplay between rexinoid signaling and myogenic regulatory factor-associated chromatin state in myogenic differentiation
por: Hamed, Munerah, et al.
Publicado: (2017)

UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts
por: Williams, Adele P., et al.
Publicado: (2019)

Transcriptomic signature of Bexarotene (Rexinoid LGD1069) on mammary gland from three transgenic mouse mammary cancer models
por: Abba, Martin C, et al.
Publicado: (2008)

PML–RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation
por: Kamashev, Dmitrii, et al.
Publicado: (2004)

9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts
por: Marayati, Raoud, et al.
Publicado: (2020)

The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in Kras(G12D); Pdx1-Cre (KC) mice
por: Leal, Ana S., et al.
Publicado: (2019)

Identification of biomarkers regulated by rexinoids (LGD1069, LG100268 and Ro25-7386) in human breast cells using Affymetrix microarray
por: SEO, HYE-SOOK, et al.
Publicado: (2015)

Vitamin D Receptor Mediates a Myriad of Biological Actions Dependent on Its 1,25‐Dihydroxyvitamin D Ligand: Distinct Regulatory Themes Revealed by Induction of Klotho and Fibroblast Growth Factor‐23
por: Haussler, Mark R, et al.
Publicado: (2020)

Pomegranate derivative urolithin A enhances vitamin D receptor signaling to amplify serotonin-related gene induction by 1,25-dihydroxyvitamin D
por: Livingston, Sarah, et al.
Publicado: (2020)

Optimal vitamin D spurs serotonin: 1,25-dihydroxyvitamin D represses serotonin reuptake transport (SERT) and degradation (MAO-A) gene expression in cultured rat serotonergic neuronal cell lines
por: Sabir, Marya S., et al.
Publicado: (2018)

A Preclinical Study of an (125)I-Labeled PSMA Ligand for Prostate-Cancer Puncture
por: Luan, Xiaohui, et al.
Publicado: (2022)

Preclinical Development of siRNA Therapeutics for AL Amyloidosis
por: Hovey, Beth M., et al.
Publicado: (2011)

Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas
por: Warda, Ankedo, et al.
Publicado: (2023)

Intrauterine Device Training Workshop for Preclinical Medical Students
por: Field, Carlie, et al.
Publicado: (2019)

Comparative cost-effectiveness of focal and total salvage (125)I brachytherapy for recurrent prostate cancer after primary radiotherapy
por: Peters, Max, et al.
Publicado: (2016)

Rewiring Tumor Cell State in Cancer Therapy: Comment on ‘9-cis-UAB30, a Novel Rexinoid Agonist, Decreases Tumorigenicity and Cancer Cell Stemness of Human Neuroblastoma Patient-Derived Xenografts’ by ‘Elizabeth Beierle et al.’
por: Chakraborty, Abhishek A.
Publicado: (2020)

Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples
por: Thomas, D S, et al.
Publicado: (2015)

Dehydroabietic oximes halt pancreatic cancer cell growth in the G1 phase through induction of p27 and downregulation of cyclin D1
por: Kolsi, Laura E., et al.
Publicado: (2018)

Low serum 1,25(OH)(2)D(3) in end-stage renal disease: is reduced 1α-hydroxylase the only problem?
por: Huish, Sharon A, et al.
Publicado: (2021)

Effectiveness of portable air filtration on reducing indoor aerosol transmission: preclinical observational trials
por: Lee, J.H., et al.
Publicado: (2022)

Sample Aging Profoundly Reduces Monocyte Responses in Human Whole Blood Cultures
por: Grievink, H. W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fd7luqcpthd7hgm638fqds8rjd